title: The renal effects of SGLT2 inhibitors and a mini-review of the literature.
abstract: Sodium-glucose linked transporter 2 (SGLT2) inhibitors are a new and promising class of antidiabetic agents which target renal tubular glucose reabsorption. Their action is based on the blockage of SGLT2 sodium-glucose cotransporters that are located at the luminal membrane of tubular cells of the proximal convoluted tubule, inducing glucosuria. It has been proven that they significantly reduce glycated hemoglobin (HbA1c), along with fasting and postprandial plasma glucose in patients with type 2 diabetes mellitus (T2DM). The glucosuria-induced caloric loss as well as the osmotic diuresis significantly decrease body weight and blood pressure, respectively. Given that SGLT2 inhibitors do not interfere with insulin action and secretion, their efficacy is sustained despite the progressive β-cell failure in T2DM. They are well tolerated, with a low risk of hypoglycemia. Their most frequent adverse events are minor: genital and urinal tract infections. Recently, it was demonstrated that empagliflozin presents a significant cardioprotective effect. Although the SGLT2 inhibitors' efficacy is affected by renal function, new data have been presented that some SGLT2 inhibitors, even in mild and moderate renal impairment, induce significant HbA1c reduction. Moreover, recent data indicate that SGLT2 inhibition has a beneficial renoprotective effect. The role of this review paper is to explore the current evidence on the renal effects of SGLT2 inhibitors.
authors.affiliation: Athens Naval Hospital, Athens, Greece.
authors.forename: Vasileios
authors.initials: V
authors.lastname: Andrianesis
authors.affiliation: Metaxa General Hospital, Athens, Greece.
authors.forename: Spyridoula
authors.initials: S
authors.lastname: Glykofridi
authors.affiliation: Iatriko Paleou Falirou Medical Center, 36 Areos Street, 17562, Paleo Faliro, Athens, Greece.
authors.forename: John
authors.initials: J
authors.lastname: Doupis
keywords: SGLT transporters; SGLT2 inhibitors; albuminuria; glucosuria; hyperfiltration; renal impairment; renoprotection; tubulointerstitial fibrosis; type 2 diabetes